secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000950170-25-025238
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health names Michael Handley COO and President of Tivic Biopharma following Statera license
--------------------------------------------------------------------------------

- Handley appointed COO and President of new Tivic Biopharma division, effective Feb 18, 2025.
- Compensation: $300k base salary, up to 35% bonus, 600k RSUs vesting over 4 years.
- Handley previously CEO of Statera Biopharma; helped commercialize 17 drugs/devices worth ~$7B in sales.
- Role includes advancing late-stage Entolimod (TLR5 agonist) for radiation protection and immune indications.
- Appointment follows Feb 11 exclusive license of Entolimod from Statera, previously disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/0000950170-25-025238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/tivc-20250218.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-025238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer